Dade completes sale of Bartels:
This article was originally published in Clinica
Dade International has completed the sale of its Bartels subsidiary to Intracel, a supplier of genetically engineered viral proteins and antibodies. Bartels has been up for sale since Dade decided earlier this year that the viral test and reagent business was outside its core activities (see Clinica No 661, p 13). Based in Cambridge, Massachusetts, Intracel has 45 employees. Terms of the transaction were not disclosed.
You may also be interested in...
ConMed Corp. is company of two halves ̶ general surgery and orthopedics – and is readying itself for a renewed assault on these two markets on the back of a technology pipeline, targeted acquisitions and a new growth-winning culture, says CFO Todd Garner.
Drug pricing and access issues expose the pharmaceutical sector especially acutely to calls for companies to meet ethical and social goals, alongside commercial ones. Digital is up-ending pharma’s processes, its workplaces and its consumers. R&D productivity is spluttering. Amid this turmoil, CEOs highlight company culture – the way an organization behaves – as a crucial ingredient for success. But what is a “right” culture? Organizational culture is neither static nor singular. It is continuously influenced by acquisitions, markets, new technologies and new generations. And pharma’s history suggests that culture change cannot happen without sufficient people change.